Treatment With Tildren®

(tiludronate disodium)

Tildren® (tiludronate disodium) will be administered to your horse through an intravenous infusion. It is administered over a 90-minute period.

Tildren® is most effective when used in conjunction with corrective farriery and a controlled exercise program. Visit with your veterinarian to learn more about management and care after Tildren® has been given.

Product Safety

In a controlled 6-month open use field study1, Tildren® (tiludronate disodium) was evaluated under strict conditions. Horses were observed for four hours following infusion and adverse events were recorded.

treatment horse bm

The most common observations were clinical signs associated with colic, which are defined as outlined below. While colic may occur, clinical signs and incidence vary and may be intermittent.

Clinical signs that were considered to be indicative of colic:

Pawing, getting up and down, pacing, restlessness, rolling, trying to roll, looking or biting at side, stretching out/straining, kicking at belly/walls, repeatedly shifting weight behind.

1 Freedom of Information Summary. NADA #141-420. Approved February 13, 2014.

TILUDRONATE, Bibliography May 2016, Studies: 2003 to 2016, Source: PubMed

A Statement From Dr. Dave Ellefson Regarding Bisphosphonate Use

Dosing and Administration

Tildren® is administered through a single intravenous infusion of 1mg/kg (0.45mg/lb) in 0.9% Sodium Chloride, and is given slowly and evenly over 90 minutes. Of the administered dose, 30-50% of the tiludronate disodium distributes to the bone within 12 hours of dosing.

Bone concentrations are higher than plasma concentrations as early as 12 hours post-administration. The drug is slowly, but continuously, released in relation to the bone remodeling process and concentrations are still present at 6 months, but lower than at 3 months, in the bone.

treatment graph bm
back to top

Do not use in horses with impaired renal function or with a history of renal disease. NSAIDs should not be used concurrently with TILDREN® . Concurrent use of NSAIDs with TILDREN® may increase the risk of renal toxicity and acute renal failure. Horses should be observed closely for 4 hours post-infusion for the development of clinical signs consistent with colic or other adverse reactions.

Caution should be used when administering TILDREN® to horses with conditions affecting mineral or electrolyte homeostasis (e.g. HYPP, hypocalcemia) and conditions which may be exacerbated by hypocalcemia (e.g. cardiac disease). The safe use of TILDREN® has not been evaluated in horses less than 4 years of age, in pregnant or lactating mares, or in breeding horses. See package insert for full prescribing information.